Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.

Peter Johann RaubenheimerWilliam C CushmanAlvaro AvezumJan BasileIgnacio Conget Donlo Gilles R DagenaisAnastasia HooverPetr JanskyFernando LanasLawrence A LeiterPatricio Lopez-JaramilloNana PogosovaJeffrey ProbstfieldPurnima Rao-MelaciniLars RydénWayne H-H SheuTheodora Temelkova-KurktschievUlagamadesan Venkatesan

Published in: Diabetes, obesity & metabolism (2022)

This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.

Keyphrases

atrial fibrillation
catheter ablation
cardiovascular disease
heart failure
study protocol
clinical trial
risk factors
electronic health record
oral anticoagulants
left atrial appendage
phase iii
big data
phase ii
coronary artery disease
combination therapy
left ventricular
data analysis